New drug combo for weight loss enters early human testing

NCT ID NCT06916065

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called eloralintide, alone or combined with tirzepatide, in 188 adults with overweight or obesity. The main goals are to check safety, side effects, and how the drugs move through the body. Participants receive weekly injections under the skin for up to 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Eloralintide and tirzepatide
What this could lead to: If successful, this could point toward a new weight-loss treatment option for people with overweight or obesity.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not on weight loss. It is small and may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Anaheim Clinical Trials, LLC

Anaheim, California, 92801, United States
Fortrea Clinical Research Unit

Daytona Beach, Florida, 32117, United States
Fortrea Clinical Research Unit

Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.